Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL SHINGLES TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL SHINGLES TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL SHINGLES TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMOLOGY
6.1 INCIDENCE RATE
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR XX
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.14 CURRENT DEVELOPMENT SCENARIO
11 MARKET OVERVIEW
11.1 DRIVERS
11.2 RESTRAINS
11.3 OPPURTUNITY
11.4 CHALLENGES
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 GLOBAL SHINGLES TREATMENT MARKET, BY TYPE
(NOTE: MARKET VALUE, VOLUME AND ASP ANALYSIS WOULD BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS OF PRODUCT)
14.1 OVERVIEW
14.2 MEDICATION
14.2.1 ANTIVIRALS
14.2.1.1. ACYCLOVIR
14.2.1.2. VALACYCLOVIR
14.2.1.3. FAMCICLOVIR
14.2.2 ANALGESICS
14.2.2.1. IBUPROFEN
14.2.2.2. ACETAMENOPHEN
14.2.3 OPIODS
14.2.3.1. OXYCODONE
14.2.3.2. HYDROCODONE
14.2.3.3. TRAMADOL
14.2.3.4. OTHERS
14.2.4 TRICYCLIC ANTIDEPRESSANTS
14.2.4.1. AMITRIPTYLINE
14.2.4.2. DESIPRAMINE
14.2.4.3. TOFRANIL
14.2.4.4. OTHERS
14.2.5 ANTICONVULSANTS
14.2.5.1. GABAPENTIN
14.2.5.2. PREGABALIN
14.2.5.3. OTHERS
14.2.6 TOPICAL TREATMENTS
14.2.6.1. CREAMS
14.2.6.1.1. ZOSTRIX
14.2.6.1.2. CAPZASIN
14.2.6.2. PATCHES
14.2.6.2.1. LIDODERM
14.2.6.2.2. LIDOCAINE GEL
14.2.7 CORTICOSTEROIDS
14.2.7.1. PREDNISONE
14.2.7.2. METHYLPREDNISONE
14.2.8 OTHERS
14.3 VACCINATION
14.3.1 VACCINATION, BY TYPE
14.3.1.1. LIVE ATTENUATED VACCINE
14.3.1.2. RECOMBINANT VACCINE
14.3.2 VACCINATION, BY BRAND
14.3.2.1. SHINGRIX
14.3.2.2. ZOSTAVAX
14.3.2.3. ZOVINEX
14.3.2.4. OTHERS
15 GLOBAL SHINGLES TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.3 PARENTERAL
15.4 TOPICAL
15.5 OTHERS
16 GLOBAL SHINGLES TREATMENT MARKET, BY AGE GROUP
16.1 OVERVIEW
16.2 PEDIATRIC
16.3 ADULT
16.4 GERIATRIC
17 GLOBAL SHINGLES TREATMENT MARKET, BY DRUG TYPE
17.1 OVERVIEW
17.2 PRESCRIPTION DRUG
17.3 OTC DRUG
18 GLOBAL SHINGLES TREATMENT MARKET, BY END USER
18.1 OVERVIEW
18.2 HOSPITALS
18.3 SPECIALTY CLINIC
18.4 HOMECARE
18.5 OTHERS
19 GLOBAL SHINGLES TREATMENT MARKET, BY DISTRIBUTION CHANNEL
19.1 OVERVIEW
19.2 HOSPITAL PHARMACY
19.3 ONLINE PHARMACY
19.4 RETAIL PHARMACY
20 GLOBAL SHINGLES TREATMENT MARKET, SWOT AND DBMR ANALYSIS
21 GLOBAL SHINGLES TREATMENT MARKET, COMPANY LANDSCAPE
21.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
21.2 COMPANY SHARE ANALYSIS: EUROPE
21.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21.4 MERGERS & ACQUISITIONS
21.5 NEW PRODUCT DEVELOPMENT & APPROVALS
21.6 EXPANSIONS
21.7 REGULATORY CHANGES
21.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
22 GLOBAL SHINGLES TREATMENT MARKET, BY GEOGRAPHY
LOBAL SHINGLES TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.1 NORTH AMERICA
22.1.1 U.S.
22.1.1.1. U.S. SHINGLES TREATMENT MARKET, BY TYPE
22.1.1.2. U.S. SHINGLES TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
22.1.1.3. U.S. SHINGLES TREATMENT MARKET, BY AGE GROUP
22.1.1.4. U.S. SHINGLES TREATMENT MARKET, BY DRUG TYPE
22.1.1.5. U.S. SHINGLES TREATMENT MARKET, BY END USER
22.1.1.6. U.S. SHINGLES TREATMENT MARKET, BY DISTRUBUTION CHANNEL
22.1.2 CANADA
22.1.3 MEXICO
22.2 EUROPE
22.2.1 GERMANY
22.2.2 FRANCE
22.2.3 U.K.
22.2.4 HUNGARY
22.2.5 LITHUANIA
22.2.6 AUSTRIA
22.2.7 IRELAND
22.2.8 NORWAY
22.2.9 POLAND
22.2.10 ITALY
22.2.11 SPAIN
22.2.12 RUSSIA
22.2.13 TURKEY
22.2.14 NETHERLANDS
22.2.15 SWITZERLAND
22.2.16 REST OF EUROPE
22.3 ASIA-PACIFIC
22.3.1 JAPAN
22.3.2 CHINA
22.3.3 SOUTH KOREA
22.3.4 INDIA
22.3.5 AUSTRALIA
22.3.6 SINGAPORE
22.3.7 THAILAND
22.3.8 MALAYSIA
22.3.9 INDONESIA
22.3.10 PHILIPPINES
22.3.11 VIETNAM
22.3.12 REST OF ASIA-PACIFIC
22.4 SOUTH AMERICA
22.4.1 BRAZIL
22.4.2 ARGENTINA
22.4.3 PERU
22.4.4 COLOMBIA
22.4.5 VENEZUELA
22.4.6 REST OF SOUTH AMERICA
22.5 MIDDLE EAST AND AFRICA
22.5.1 SOUTH AFRICA
22.5.2 SAUDI ARABIA
22.5.3 UAE
22.5.4 EGYPT
22.5.5 KUWAIT
22.5.6 ISRAEL
22.5.7 REST OF MIDDLE EAST AND AFRICA
22.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23 GLOBAL SHINGLES TREATMENT MARKET, COMPANY PROFILE
23.1 GLAXOSMITHKLINE PLC
23.1.1 COMPANY OVERVIEW
23.1.2 REVENUE ANALYSIS
23.1.3 GEOGRAPHIC PRESENCE
23.1.4 PRODUCT PORTFOLIO
23.1.5 RECENT DEVELOPMENTS
23.2 PFIZER INC.
23.2.1 COMPANY OVERVIEW
23.2.2 REVENUE ANALYSIS
23.2.3 GEOGRAPHIC PRESENCE
23.2.4 PRODUCT PORTFOLIO
23.2.5 RECENT DEVELOPMENTS
23.3 VIATRIS INC.
23.3.1 COMPANY OVERVIEW
23.3.2 REVENUE ANALYSIS
23.3.3 GEOGRAPHIC PRESENCE
23.3.4 PRODUCT PORTFOLIO
23.3.5 RECENT DEVELOPMENTS
23.4 NOVARTIS
23.4.1 COMPANY OVERVIEW
23.4.2 REVENUE ANALYSIS
23.4.3 GEOGRAPHIC PRESENCE
23.4.4 PRODUCT PORTFOLIO
23.4.5 RECENT DEVELOPMENTS
23.5 GLENMARK PHARMACEUTICALS INC.
23.5.1 COMPANY OVERVIEW
23.5.2 REVENUE ANALYSIS
23.5.3 GEOGRAPHIC PRESENCE
23.5.4 PRODUCT PORTFOLIO
23.5.5 RECENT DEVELOPMENTS
23.6 TEVA PHARMACEUTICALS USA, INC.
23.6.1 COMPANY OVERVIEW
23.6.2 REVENUE ANALYSIS
23.6.3 GEOGRAPHIC PRESENCE
23.6.4 PRODUCT PORTFOLIO
23.6.5 RECENT DEVELOPMENTS
23.7 SORRENTO THERAPEUTICS.
23.7.1 COMPANY OVERVIEW
23.7.2 REVENUE ANALYSIS
23.7.3 GEOGRAPHIC PRESENCE
23.7.4 PRODUCT PORTFOLIO
23.7.5 RECENT DEVELOPMENTS
23.8 AKORN OPERATING COMPANY LLC
23.8.1 COMPANY OVERVIEW
23.8.2 REVENUE ANALYSIS
23.8.3 GEOGRAPHIC PRESENCE
23.8.4 PRODUCT PORTFOLIO
23.8.5 RECENT DEVELOPMENTS
23.9 EMCURE PHARMACEUTICALS LIMITED
23.9.1 COMPANY OVERVIEW
23.9.2 REVENUE ANALYSIS
23.9.3 GEOGRAPHIC PRESENCE
23.9.4 PRODUCT PORTFOLIO
23.9.5 RECENT DEVELOPMENTS
23.1 HETERO HEALTHCARE LIMITED.
23.10.1 COMPANY OVERVIEW
23.10.2 REVENUE ANALYSIS
23.10.3 GEOGRAPHIC PRESENCE
23.10.4 PRODUCT PORTFOLIO
23.10.5 RECENT DEVELOPMENTS
23.11 MSN LABORATORIES
23.11.1 COMPANY OVERVIEW
23.11.2 REVENUE ANALYSIS
23.11.3 GEOGRAPHIC PRESENCE
23.11.4 PRODUCT PORTFOLIO
23.11.5 RECENT DEVELOPMENTS
23.12 ANI PHARMACEUTICALS, INC.
23.12.1 COMPANY OVERVIEW
23.12.2 REVENUE ANALYSIS
23.12.3 GEOGRAPHIC PRESENCE
23.12.4 PRODUCT PORTFOLIO
23.12.5 RECENT DEVELOPMENTS
23.13 RUBICON RESEARCH PVT. LTD.
23.13.1 COMPANY OVERVIEW
23.13.2 REVENUE ANALYSIS
23.13.3 GEOGRAPHIC PRESENCE
23.13.4 PRODUCT PORTFOLIO
23.13.5 RECENT DEVELOPMENTS
23.14 MERCK & CO., INC
23.14.1 COMPANY OVERVIEW
23.14.2 REVENUE ANALYSIS
23.14.3 GEOGRAPHIC PRESENCE
23.14.4 PRODUCT PORTFOLIO
23.14.5 RECENT DEVELOPMENTS
23.15 DR. REDDY’S LABORATORIES, INC.
23.15.1 COMPANY OVERVIEW
23.15.2 REVENUE ANALYSIS
23.15.3 GEOGRAPHIC PRESENCE
23.15.4 PRODUCT PORTFOLIO
23.15.5 RECENT DEVELOPMENTS
23.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
23.16.1 COMPANY OVERVIEW
23.16.2 REVENUE ANALYSIS
23.16.3 GEOGRAPHIC PRESENCE
23.16.4 PRODUCT PORTFOLIO
23.16.5 RECENT DEVELOPMENTS
23.17 CHANGCHUN BCHT BIOTECHNOLOGY CO.
23.17.1 COMPANY OVERVIEW
23.17.2 REVENUE ANALYSIS
23.17.3 GEOGRAPHIC PRESENCE
23.17.4 PRODUCT PORTFOLIO
23.17.5 RECENT DEVELOPMENTS
23.18 NOVO MEDI SCIENCES PVT. LTD.
23.18.1 COMPANY OVERVIEW
23.18.2 REVENUE ANALYSIS
23.18.3 GEOGRAPHIC PRESENCE
23.18.4 PRODUCT PORTFOLIO
23.18.5 RECENT DEVELOPMENTS
24 RELATED REPORTS
25 CONCLUSION
26 QUESTIONNAIRE
27 ABOUT DATA BRIDGE MARKET RESEARCH
